Business Context and Reporting Period
This Form 8-K Current Report was filed by TriSalus Life Sciences, Inc. on April 29, 2026, covering events occurring on April 24, 2026. The filing addresses personnel changes within the company's executive leadership.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel matters.
Material Changes
- Departure of Officer: Jodi Devlin notified the company of her intention to retire as Chief of Clinical Operations, effective October 1, 2026.
- Appointment of Officer: Dr. Richard Marshall was appointed as Chief Medical Officer, effective June 29, 2026 (previously announced on April 7, 2026).
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of material risks and contingencies. Management commentary is limited to expressing gratitude for Ms. Devlin's contributions.
Key Facts for Investor Verification
- Confirm the effective date of Jodi Devlin's retirement (October 1, 2026) and any interim arrangements for the Chief of Clinical Operations role.
- Verify the start date and background of Dr. Richard Marshall as the new Chief Medical Officer (June 29, 2026).
- Check for any subsequent filings regarding the transition of clinical operations responsibilities.